Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PYRIMIDINE COMPOUNDS USEFUL AS TYROSINE KINASE INHIBITORS
Document Type and Number:
WIPO Patent Application WO/2019/126136
Kind Code:
A3
Abstract:
The present disclosure provides pyrimidine compounds useful as tyrosine kinase inhibitors, and particularly epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) inhibitors. The disclosed EGFR inhibitors are effective against acquired resistance mutations appearing after treatment of existing EGFR inhibitors. The present disclosure also provides methods of treating cancer using pyrimidine compounds and pharmaceutical compositions comprising pyrimidine compounds. The methods of treating cancer may be directed to cancer with acquired resistance mutations.

Inventors:
YANG LIHU (US)
MA GUANGNING (CN)
CUI YINGJIE (CN)
Application Number:
PCT/US2018/066185
Publication Date:
August 08, 2019
Filing Date:
December 18, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
STERNGREENE INC (US)
International Classes:
A61K31/505; A61P35/00; C07D239/32
Foreign References:
US20140309246A12014-10-16
US6284764B12001-09-04
US5457105A1995-10-10
Other References:
DATABASE PUBCHEM COMPOUND 21 March 2013 (2013-03-21), ANONYMOUS: "N-Phenyl-6-propylquinazolin-4-amine", XP055628185, retrieved from NCBI Database accession no. CID70898473
FANG ET AL.: "Design, synthesis, and evaluation of substituted 6-amide-4-anilinoquinazoline derivatives as c-Src inhibitors", RSC ADVANCES, vol. 3, no. 48, 24 October 2013 (2013-10-24), pages 26230 - 26240, XP055628188
Attorney, Agent or Firm:
LI, Shawn S. (US)
Download PDF: